Interpace Diagnostics Announces Timing of Earnings Release and Investor Conference Call
March 14 2018 - 2:30PM
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (the “Company”), a
fully integrated commercial and bioinformatics company that
provides clinically useful molecular diagnostic tests and pathology
services, announced today that it will release its 2017 year-end
and fourth quarter financial results on Thursday, March 15, 2018
and will host an investor conference call at 4:30 p.m. EDT.
The live webcast and subsequent replay may be accessed by
visiting Interpace’s website www.interpacediagnostics.com.
Alternatively, please call 1-888-394-8218 (U.S.) or
1-323-701-0225 (international) to listen to the live conference
call. The conference ID number is 5146319. The webcast replay will
be available on the company’s website within 24 hours following
completion of the call and archived on the company’s website for 90
days.
About Interpace Diagnostics Group,
Inc.
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management. The Company
currently has four commercialized molecular tests and one test in a
clinical evaluation process (CEP); PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGenX®, for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
next generation sequencing assay; ThyraMIR®, for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX™ that differentiates lung cancer of
primary vs. metastatic origin. BarreGEN® for Barrett's
Esophagus, is currently being “soft launched” with key opinion
leaders as we continue to gather data on this assay that will
assist us in seeking favorable reimbursement as well as important
clinical information. Barrett's Esophagus is a rapidly growing
diagnosis that affects over three million people in the US and over
time can progress to esophageal cancer. The Company’s data base
includes data from over 45,000 patients who have been tested using
the Company’s current products, including over 15,000 molecular
tests for thyroid nodules. Interpace has been designated as one of
the top 20 companies for providing bioinformatics solutions.
Interpace’s mission is to provide personalized medicine
through molecular diagnostics, innovation and data to advance
patient care based on rigorous science. For more information,
please visit Interpace’s website
at www.interpacediagnostics.com
CONTACTS:
Interpace DiagnosticsInvestor Relations:Paul Kuntz(412)
708-4590RedchipPaul@Redchip.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024